EW|Analyst Targets
EW|Company Info
EW|Insider Trading
EW|Fundamentals
EW|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.74 | - | - |
| Q2'26 | $0.74 | $0.78 | +5.1% |
| Q1'26 | $0.75 | $0.78 | +4.1% |
| Q4'25 | $0.69 | $0.58 | -16.0% |
| Q3'25 | $0.59 | $0.67 | +12.6% |
| Q2'25 | $0.62 | $0.67 | +7.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.7B | - | - |
| Q2'26 | $1.7B | $1.7B | +2.4% |
| Q1'26 | $1.6B | $1.6B | +0.3% |
| Q4'25 | $1.6B | $1.6B | +0.2% |
| Q3'25 | - | $1.6B | - |
| Q2'25 | - | $1.5B | - |
EW|Monthly Returns
Market Data
EW Stock Snapshot
- Market cap
- 49.38B
- P/E ratio
- 49.1
- Day range
- $84.83 – $86.62
- News sentiment
- 55/100 · Neutral
- Analyst target
- $101.96 (+17.9%)
- Consensus
- Buy · 42 analysts
The technical read on EW is balanced, which usually means the market is waiting on a catalyst. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.
Reverse DCF
What growth is priced into EW?
At today's price, Edwards Lifesciences Corporation needs to grow free cash flow about 20.2% a year for the next 10 years to justify its valuation at a 8.47% cost of capital. Over its actual history it has compounded free cash flow at 12.3% a year, so the market is asking for 7.9 percentage points above its own delivered rate. On that basis EW looks priced above what its own growth record supports.
- Implied FCF growth
- 20.2%
- Historical FCF CAGR
- 12.3%
- Growth gap
- +7.9 pts
- Verdict
- RICH
- Discount rate (WACC)
- 8.47%
- Beta
- 0.65
Behaviour On Record
What EW's own history says about today's numbers
- Realized volatility (21d)
- 24.7% 40th pct
- Below its peak
- -34.7%
- vs 200-day average
- +0.2%
- Up days (1y)
- 51%
Edwards Lifesciences Corporation is currently running 24.7% annualised volatility over the last 21 sessions. Measured against EW's own 13 years of daily returns rather than a market-wide average, that is the 40th percentile — close to its own typical level, against a typical reading of 26.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
EW is trading -34.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.4%, and the deepest was -46.3% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +0.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 29th percentile — a narrower gap than it typically runs. Over the past year EW closed higher on 51% of sessions, and it is currently 1 session into a falling streak.
On October specifically: over 13 years of records, EW finished the month higher 6 of 13 times, with a median return of -6.4% and an average of -2.6%. Its strongest month historically has been November at +4.7% on average, its weakest October at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: EW has opened more than 2% away from the prior close in 118 of 3,267 sessions (3.6% of the time), with the largest gaps running +11.0% and -13.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, EW moved an average of 2.1% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.3% and a largest of -5.5%.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against EW's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of EW's sector?
Edwards Lifesciences Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, EW ranks 3rd of 15 tracked industries, leading.
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
- Industry rank
- #3 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on EW?
Barclays most recently initiated coverage on Edwards Lifesciences Corporation to Overweight on Oct 7, 2026 with a price target of $110. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- Barclays — Overweight
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Peers & ETF holders
EW peers & ETF holders
Medical DevicesMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▼ Sell | 70,079,435 | 12.10% | $5.97B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 58,789,433 | 10.15% | $5.32B | 2026-08-07 |
| JPMorgan Chase & Co | ▲ Buy | 22,783,175 | 3.93% | $2.08B | 2026-08-12 |
| Wellington Management Group LLP | ▼ Sell | 16,827,967 | 2.91% | $1.52B | 2026-08-14 |
| Geode Capital Management, LLC | ▲ Buy | 15,437,251 | 2.67% | $1.39B | 2026-08-12 |
| FMR LLC (Fidelity) | ▼ Sell | 8,435,949 | 1.46% | $763.12M | 2026-08-13 |
| Norges Bank | ▼ Sell | 8,373,783 | 1.45% | $757.49M | 2026-08-12 |
| AllianceBernstein L.P. | ▲ Buy | 8,660,416 | 1.50% | $693.53M | 2026-08-14 |
| Bank of America Corp | ▲ Buy | 6,692,424 | 1.16% | $605.40M | 2026-08-14 |
| Artisan Partners Limited Partnership | ▲ Buy | 6,625,703 | 1.14% | $599.36M | 2026-08-13 |
| Morgan Stanley | ▼ Sell | 6,339,368 | 1.09% | $573.46M | 2026-08-13 |
| Northern Trust Corp | ▼ Sell | 5,671,229 | 0.98% | $513.02M | 2026-08-13 |
| Goldman Sachs Group Inc | ▼ Sell | 4,549,113 | 0.79% | $411.51M | 2026-08-14 |
| Citadel Advisors LLC | ▲ Buy | 3,997,925 | 0.69% | $361.65M | 2026-09-02 |
| Invesco Ltd. | ▼ Sell | 3,977,518 | 0.69% | $359.81M | 2026-08-14 |
| Millennium Management LLC | ▲ Buy | 3,584,795 | 0.62% | $324.28M | 2026-08-14 |
| Neuberger Berman Group LLC | ▲ Buy | 2,886,953 | 0.50% | $261.24M | 2026-08-13 |
| Point72 Asset Management, L.P. | ▼ Sell | 1,774,120 | 0.31% | $160.49M | 2026-08-14 |
| Two Sigma Investments, LP | ▲ Buy | 1,521,899 | 0.26% | $137.67M | 2026-08-14 |
| AQR Capital Management LLC | ▼ Sell | 1,465,185 | 0.25% | $132.17M | 2026-08-14 |
| Baillie Gifford & Co | ▲ Buy | 1,208,945 | 0.21% | $109.36M | 2026-08-06 |
| Citigroup Inc | ▲ Buy | 1,199,364 | 0.21% | $108.49M | 2026-08-03 |
| Wells Fargo & Company | ▼ Sell | 1,041,675 | 0.18% | $94.23M | 2026-08-14 |
| Janus Henderson Group plc | ▲ Buy | 1,165,604 | 0.20% | $93.33M | 2026-05-18 |
| Man Group plc | ▼ Sell | 935,186 | 0.16% | $84.60M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Josh Gottheimer | House | NJ05 | ▼ Sell | $1K - $15K | 2025-11-19 | 2025-12-29 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $50K - $100K | 2025-05-12 | 2025-06-22 |
| Bruce Westerman | House | AR04 | ▼ Sell | $1K - $15K | 2025-04-21 | 2025-05-12 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-04-08 | 2025-05-08 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-04-07 | 2025-05-08 |
| Bruce Westerman | House | AR04 | ▲ Buy | $1K - $15K | 2025-03-03 | 2025-04-16 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2023-04-03 | 2023-05-12 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2021-03-29 | 2021-07-23 |